Answers are grounded in this paper and cite their sources.
Despite advances in antiretroviral therapy, toxicity problems, emergence of drug-resistant HIV-1 (human immunodeficiency virus 1) strains and viral reservoirs, emphasize the urgent need for new anti-HIV drugs. Withaferin A, a natural steroidal lactone first isolated from the medicinal plant Withania somnifera (L.) Dunal (Ashwagandha), has emerged as a promising lead scaffold with proven pharmacological properties. Based on previous studies highlighting the therapeutic potential of withaferin A and the emerging role of organosilicon motifs in drug design, we explored and enlarged the chemical space of this steroidal framework as a basis to broaden the current antiretroviral chemotherapy. The present study reports the synthesis of thirty withaferin A-silyl ether analogues, including two twin compounds and three silyl-ester analogues reported for the first time. The antiretroviral activity of this compound series was evaluated, and five inhibitors were selected for mechanistic studies to define their mechanism of action in the HIV-1 replication cycle. Withaferin A and the selected analogues primarily acts through viral integration and post-transcriptional stages. Notably, some analogues redirect the withaferin A main mechanism, also affecting HIV envelope and reverse transcription. This multi-step behaviour may provide an advantage to overcome the drawbacks of the current therapy. In addition, structure-activity relationships and in silico ADME studies were employed to understand the structural requirements and pharmacokinetic properties of this series of analogues. The results herein underscore withaferin A as a versatile structural platform to develop new antiretroviral drugs.
No takes yet. Share an insight, caveat, or question.
González-Linares et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: